A Cambridge UK anti-inflammatory drug has been acquired by German pharma giant Boehringer Ingelheim for an undisclosed sum, allowing some of the early investors to partially exit the University spin-out.
Boehringer is acquiring the global rights to Funxional Therapeutics’ FX125L technology – a compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients after successful Phase 1 studies in the US.
